期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 21, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/ijms21051625
关键词
retinitis pigmentosa; cone photoreceptor; central vision; rod-derived cone viability factor; aerobic glycolysis; thioredoxin signaling; gene therapy; adeno-associated viral vector; chemical manufacturing; clinical trial
资金
- SparingVision
- Institut National pour la RechercheMedicale (INSERM), Sorbonne University
- Centre National Hospitalier des Quinze-Vingts (CHNO)
- Agence Nationale pour la Recherche (ANR)
- Fondation pour la Recherche Medicale (FRM)
- Fondation Voir et Entendre (FVE)
- foundation fighting blindness (FFB)
The loss of cone photoreceptor function in retinitis pigmentosa (RP) severely impacts the central and daily vision and quality of life of patients affected by this disease. The loss of cones follows the degeneration of rods, in a manner independent of the causing mutations in numerous genes associated with RP. We have explored this phenomenon and proposed that the loss of rods triggers a reduction in the expression of rod-derived cone viability factor (RdCVF) encoded by the nucleoredoxin-like 1 (NXNL1) gene which interrupts the metabolic and redox signaling between rods and cones. After providing scientific evidence supporting this mechanism, we propose a way to restore this lost signaling and prevent the cone vision loss in animal models of RP. We also explain how we could restore this signaling to prevent cone vision loss in animal models of the disease and how we plan to apply this therapeutic strategy by the administration of both products of NXNL1 encoding the trophic factor RdCVF and the thioredoxin enzyme RdCVFL using an adeno-associated viral vector. We describe in detail all the steps of this translational program, from the design of the drug, its production, biological validation, and analytical and preclinical qualification required for a future clinical trial that would, if successful, provide a treatment for this incurable disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据